Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group (Q33398249)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group |
scientific article |
Statements
1 reference
Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group (English)
1 reference
Dorte Lisbet Nielsen
1 reference
Karsten D Bjerre
1 reference
Erik H Jakobsen
1 reference
Søren Cold
1 reference
Lars Stenbygaard
1 reference
Peter G Sørensen
1 reference
Claus Kamby
1 reference
Susanne Møller
1 reference
Charlotte L T Jørgensen
1 reference
Michael Andersson
1 reference
14 November 2011
1 reference
1 reference
29
1 reference
36
1 reference
4748-4754
1 reference
Identifiers
1 reference
1 reference